A5057279122- Colorectal and Anal Carcinomas
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Diagnosis and treatment of tuberculosis
- Pharmaceutical Practices and Patient Outcomes
- Sarcoma Diagnosis and Treatment
- Bacterial Identification and Susceptibility Testing
- Health Systems, Economic Evaluations, Quality of Life
- Primary Care and Health Outcomes
- Intraperitoneal and Appendiceal Malignancies
- Gastric Cancer Management and Outcomes
- Brain Metastases and Treatment
- Pancreatic and Hepatic Oncology Research
- Antibiotic Use and Resistance
- Colorectal Cancer Surgical Treatments
- Glioma Diagnosis and Treatment
- Ferroptosis and cancer prognosis
- Lung Cancer Diagnosis and Treatment
- Complementary and Alternative Medicine Studies
- Advanced Radiotherapy Techniques
Leeds Teaching Hospitals NHS Trust
2025
University of Leeds
2021-2023
St James's University Hospital
2021-2023
Real-world data is an important complement to randomized controlled trials and can be used assess whether study results translate well routine clinical practice groups of patients that are often excluded from trials. The aim this disease natural history care quality assessment (DINASTY) describe treatments, outcomes for with metastatic non-small cell lung cancer using real-world data. a retrospective observational multicenter conducted within DIGICORE, non-profit European Economic Interest...
Abstract Objectives To assess the effectiveness of fluorine-18 fluorodeoxyglucose (FDG) positron-emission tomography-computed tomography (PET-CT) and magnetic resonance imaging (MRI) for response assessment post curative-intent chemoradiotherapy (CRT) in anal squamous cell carcinoma (ASCC). Methods Consecutive ASCC patients treated with CRT at a single centre between January 2018 April 2020 were retrospectively identified. Clinical meta-data including progression-free survival (PFS) overall...
Abstract Background Anal cancer is a rare with rising incidence. Despite the relatively good outcomes conferred by state-of-the-art chemoradiotherapy, further improving disease control and reducing toxicity has proven challenging. Developing validating prognostic models using routinely collected data may provide new insights for treatment development selection. However, due to rarity of cancer, it can be difficult obtain sufficient data, especially from single centres, develop validate...
Download This Paper Open PDF in Browser Add to My Library Share: Permalink Using these links will ensure access this page indefinitely Copy URL DOI
Abstract AIMS The rapid recurrence of therapy-resistant glioblastoma leaves patients with a dismal 2-year survival rate just 16%, highlighting the need to develop treatments that combat or prevent recurrence. Recently, have been stratified by their gene expression response therapy. Specifically, genes JARID2 binding sites in promoter (JBS-genes) either become up- down-regulated on progression from primary recurrent tumour. Importantly, these two responses appear employ different mechanisms...